Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Comparative Study

Review

Multicenter Study

Observational Study

Clinical Trial

Systematic Review

Clinical Trial, Phase III

Meta-Analysis

Case Reports

Evaluation Study

Publication Year

From

Quick links

Individual year

2023

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2003

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Insulin Detemir""[mesh_terms]

46 Results

Searching titles within these results

Determining the effects of insulin Detemir on endogenous secretion of insulin.

Benjamin A Van Noorden, Jacob B Klenner, Jennifer L Knopp, J Chase, Geoffrey M Shaw, Sarah L Vergeer, Anna R Hardy, Lui R Holder Pearson

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2020;2019():2943-2946

Full Text

Abstract

Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study.

Na Guo, Zhen Han, Xiaoqin Luo, Zhengfeei Ma, Jiayi Gao, Hong Zhao, Yang Mi, Zhao Yang, Zhangya He, Jing Ji

BMJ open diabetes research & care 2021;8(1):e001155

Free Full Text

Abstract

Adiponectin, Leptin, and Leptin Receptor in Obese Patients with Type 2 Diabetes Treated with Insulin Detemir.

Krystyna Olczyk, Diana Ivanova, Alicja Telega, Łukasz Mencner, Kornelia Kuźnik-Trocha, Katarzyna Winsz-Szczotka, Agnieszka Jura-Półtorak, Katarzyna Komosinska-Vassev, Robert Koprowski, Paweł Olczyk

Molecules (Basel, Switzerland) 2018;22(8):1274

Free Full Text

Abstract

Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?

D Russell-Jones, T Danne, K Hermansen, K Niswender, K Robertson, N Thalange, J R Vasselli, B Yildiz, H U Häring

Diabetes, obesity & metabolism 2016;17(10):919-27

Free Full Text

Abstract

Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care.

Louis Kuritzky, Daniel Katselnik, Ronald Goldenberg, Roopa Mehta

Annals of medicine 2021;53(1):998-1009

Free Full Text

Abstract

Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.

G B Bolli, D R Owens

Diabetes technology & therapeutics 2008;10(5):333-49

Full Text

Abstract

Insulin detemir in the treatment of type 1 and type 2 diabetes.

Jean-Christophe Philips, André Scheen

Vascular health and risk management 2007;2(3):277-83

Free Full Text

Abstract

Body Composition and Epicardial Fat in Type 2 Diabetes Patients Following Insulin Detemir Versus Insulin Glargine Initiation.

B Elisha, M Azar, N Taleb, S Bernard, G Iacobellis, R Rabasa-Lhoret

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2016;48(1):42-7

Full Text

Abstract

Insulin detemir in routine clinical practice: a 26-week follow-up in type 1 diabetic patients from the Belgian PREDICTIVE Cohort.

V Preumont, M Buysschaert, S De Beukelaer, C Mathieu

Acta clinica Belgica 2009;64(1):49-55

Full Text

Abstract

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.

Chantal Mathieu, Tim Heise

Diabetes, obesity & metabolism 2017;19(1):3-12

Free Full Text

Abstract

A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2).

Nehama Zuckerman-Levin, Ólöf Thórisdóttir, Alison Lunsford, Bo Liang, Fu-Sung Lo, Margarita Barrientos-Perez, Mark D Wheeler

European journal of pediatrics 2018;177(10):1497-1503

Free Full Text

Abstract

Basal insulin analogs: from pathophysiology to therapy. What we see, know, and try to comprehend?

C Colette, D Owens, L Monnier

Diabetes & metabolism 2014;39(6):468-76

Full Text

Abstract

Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).

Jean-Pierre Le Floch, Marc Lévy, Helen Mosnier-Pudar, Frank Nobels, Sylvie Laroche, Sophie Gonbert, Eveline Eschwege, Pierre Fontaine

Diabetes care 2013;32(1):32-7

Free Full Text

Abstract

Pharmacology of insulin detemir.

Peter Kurtzhals

Endocrinology and metabolism clinics of North America 2007;36 Suppl 1():14-20

Full Text

Abstract

Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study.

Bruno Guerci, Danièle Dubois-Laforgue, Eric Renard

Diabetes technology & therapeutics 2012;13(12):1213-8

Full Text

Abstract

Results: 1 – 15 / 46

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Insulin Detemir""[mesh_terms]

Determining the effects of insulin Detemir on endogenous secretion of insulin.

Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study.

Adiponectin, Leptin, and Leptin Receptor in Obese Patients with Type 2 Diabetes Treated with Insulin Detemir.

Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?

Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care.

Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.

Insulin detemir in the treatment of type 1 and type 2 diabetes.

Body Composition and Epicardial Fat in Type 2 Diabetes Patients Following Insulin Detemir Versus Insulin Glargine Initiation.

Insulin detemir in routine clinical practice: a 26-week follow-up in type 1 diabetic patients from the Belgian PREDICTIVE Cohort.

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.

A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2).

Basal insulin analogs: from pathophysiology to therapy. What we see, know, and try to comprehend?

Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).

Pharmacology of insulin detemir.

Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study.

Results for
""Insulin Detemir""[mesh_terms]